Screener
SG&A at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:28 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001703057-26-000046
| Line item | Three months ended June 30, 2025 | Three months ended June 30, 2026 | Six months ended June 30, 2025 | Six months ended June 30, 2026 |
|---|---|---|---|---|
| Total revenue | 17,084 | 4,050 | 21,320 | 12,362 |
| Operating expenses: | ||||
| Research and development(1) | 39,213 | 45,987 | 81,711 | 92,649 |
| Sales, general, and administrative(1) | 21,986 | 13,850 | 41,054 | 26,185 |
| Depreciation and amortization | 5,470 | 6,990 | 10,801 | 13,828 |
| Total operating expenses | 66,669 | 66,827 | 133,566 | 132,662 |
| Loss from operations | (49,585) | (62,777) | (112,246) | (120,300) |
| Other (income) expense: |
Item 1. Financial Statements (Unaudited)
FAQ
- What is AbCellera Biologics Inc.'s SG&A?
- AbCellera Biologics Inc. (ABCL) reported SG&A of $13.85M in Q2 2026.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about AbCellera Biologics Inc.'s sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude